microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A

Luo, Chu-Bin; Yin, Dan; Zhan, Hao; Borjigin, Uyunbilig; Li, Chuanjiang; Zhou, Zheng‐Jun; Hu, Zhiqiang; Wang, Pengcheng; Sun, Qiqing; Fan, Jia; Zhou, Jian; Wang, Xin; Zhou, Shao-Lai; Huang, Xiaowu

doi:10.1038/s41419-018-0577-y

Cited by 45 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, LIN7A is reported to be associated with the development of breast cancer (Gruel et al, ). Recently, Luo et al () also showed that LIN7A promotes liver cancer cell proliferation and metastasis. The specific role of LIN7A in ovarian cancer has not been revealed.…”

Section: Discussionmentioning

confidence: 95%

Long noncoding RNA CASC9 promotes LIN7A expression via miR‐758‐3p to facilitate the malignancy of ovarian cancer

Kong

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

The long noncoding RNA cancer susceptibility 9 (CASC9) has been reported to be a pivot modulator in growth and metastasis of breast cancer, liver cancer, esophageal squamous cell carcinoma, lung adenocarcinoma, gastric cancer, and nasopharyngeal cancer. However, its potential roles in ovarian cancer remain unclear. In this study, we aimed at its functions and molecular mechanism in ovarian cancer progression. We showed that CASC9 was highly expressed in ovarian cancer tissues and cell lines. An elevated level of CASC9 predicts an unfavorable prognosis in patients with ovarian cancer. Loss‐of‐function and gain‐of‐function assays illustrated that CASC9 promotes ovarian cancer cell proliferation, migration, and invasion in vitro, and accelerates tumor growth in vivo. We showed that CASC9 works as a competing endogenous RNA (ceRNA) for miR‐758‐3p which targets LIN7A. CASC9 inhibits the level of miR‐758‐3p, and in turn stimulates LIN7A expression in ovarian cancer. Overexpression of LIN7A reverses the suppressive roles of CASC9 depletion on ovarian cancer. In sum, our findings reveal a novel undefined regulatory signaling pathway, namely CASC9/miR‐758‐3p/LIN7A axis, involved in ovarian cancer progression.

show abstract

Section: Discussionmentioning

confidence: 95%

Long noncoding RNA CASC9 promotes LIN7A expression via miR‐758‐3p to facilitate the malignancy of ovarian cancer

Kong

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…MiRNAs, including miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-80, provided a high diagnostic accuracy of hepatitis B virus-related hepatocellular carcinoma [43]. Moreover, microRNA-501-3p could suppress metastasis and progression of hepatocellular carcinoma through targeting Lin-7 homolog A (LIN7A) [44]. Extracellular miRNA have been already detected in cell-exported exosomes.…”

Section: Extracellular Rna Functionmentioning

confidence: 99%

Extracellular RNA in systemic lupus erythematosus

Liu

Wang

Liu

2019

ExRNA

View full text Add to dashboard Cite

Since the discovery of extracellular RNA (exRNA), it has been shown that exRNAs play a significant role as a transducer in intercellular communication and biomarkers in various diseases. Systemic lupus erythematosus (SLE) is a kind of autoimmune disease that has protean manifestations. The survival and long-term prognosis of patients with SLE has improved in these 5-10 years, while disease pathogenesis is still not clear. Many researchers found the changes in exRNA profile, and exRNAs are likely participating in the process of SLE. In this review, we summarize the current profile and function of exRNA in SLE. Circulating miRNAs, in particular, have been identified as biomarkers for SLE diagnosis. We also explore the function of lncRNA in SLE and the potential correlation with disease progression and activity. These studies show that exRNAs may take parts in the process of SLE and some of them can be used as diagnostic tool for SLE.

show abstract

“…miR-501-3p inhibits migration, proliferation and EMT of HCCLM3 and PLC/PRF/5 HCC cells as shown by gain and loss of function experiments (178). The incidence of lung metastasis of HCCLM3 transfected with miR-501-3p cells was reduced in comparison to control cells in an orthotopic mouse model (178). LIN7A homolog A (LIN7A) was identified as a target of miR-501-3p (178).…”

Section: Mirs-137 and Mir-612 Mir-137 (mentioning

confidence: 99%

“…The incidence of lung metastasis of HCCLM3 transfected with miR-501-3p cells was reduced in comparison to control cells in an orthotopic mouse model (178). LIN7A homolog A (LIN7A) was identified as a target of miR-501-3p (178). It was shown that LIN7A mediates the effects of miR-501-3p in vivo (178).…”

Section: Mirs-137 and Mir-612 Mir-137 (mentioning

confidence: 99%

MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance

Weidle

Schmid

Birzele

et al. 2019

Cancer Genomics Proteomics

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is responsible for the second-leading cancer-related death toll worldwide. Although sorafenib and levantinib as frontline therapy and regorafenib, cabazantinib and ramicurimab have now been approved for second-line therapy, the therapeutic benefit is in the range of only a few months with respect to prolongation of survival. Aggressiveness of HCC is mediated by metastasis. Intrahepatic metastases and distant metastasis to the lungs, lymph nodes, bones, omentum, adrenal gland and brain have been observed. Therefore, the identification of metastasis-related new targets and treatment modalities is of paramount importance. In this review, we focus on metastasis-related microRNAs (miRs) as therapeutic targets for HCC. We describe miRs which mediate or repress HCC metastasis in mouse xenograft models. We discuss 18 metastasis-promoting miRs and 35 metastasis-inhibiting miRs according to the criteria as outlined. Six of the metastasispromoting miRs (miR-29a,-219-5p,-331-3p, 425-5p,-487a and-1247-3p) are associated with unfavourable clinical prognosis. Another set of six down-regulated miRs (miR-101,-129-3p,-137,-149,-503, and-630) correlate with a worse clinical prognosis. We discuss the corresponding metastasisrelated targets as well as their potential as therapeutic modalities for treatment of HCC-related metastasis. A subset of up-regulated miRs-29a,-219-5p and-425-5p and downregulated miRs-129-3p and-630 were evaluated in orthotopic metastasis-related models which are suitable to mimic HCC-related metastasis. Those miRNAs may represent prioritized targets emerging from our survey. Hepatocellular carcinoma (HCC) is the second-leading cause of cancer-related death worldwide (1). In the next couple of years, an annual incidence of one million cases is expected (1). Risk factors for HCC are non-alcohol steatohepatitis, hepatitis B and C virus (HBV/HCV), alcohol and aflatoxin (2). In Asia and Africa, 60% of HCC cases are associated with HBV, 20% are related to HCV (2). Patients with early-and intermediatestage HCC are treated with locoreginal therapies, those with advanced disease receive systemic treatment (3). Sorafenib, a multikinase tyrosine kinase inhibitor was the only approved agent between 2007 and 2016 (4). This agent gives rise to only marginal therapeutic benefit. Recently, therapeutic benefit was shown with multikinase inhibitors levantinib as frontline therapy, and regorafenib, cabazantinib and ramucirumab, a monoclonal antibody directed against vascular endothelial growth factor receptor 2, as second-line therapies (4). In addition, nivolumab, a monoclonal antibody directed against programmed cell death protein 1 (PD1) has been granted accelerated approval by the Food and Drug Administration for treatment of HCC and other checkpoint inhibitors are undergoing phase III clinical trials for this indication (5). Unsupervised clustering has revealed three subtypes of HCC based on transcriptional profiling (6) and immune phenotyping with respect to lymphocyte infiltration has discov...

show abstract

microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A

Cited by 45 publications

References 35 publications

Long noncoding RNA CASC9 promotes LIN7A expression via miR‐758‐3p to facilitate the malignancy of ovarian cancer

Long noncoding RNA CASC9 promotes LIN7A expression via miR‐758‐3p to facilitate the malignancy of ovarian cancer

Extracellular RNA in systemic lupus erythematosus

MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance

Contact Info

Product

Resources

About